Olaparib.png
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
 COA of our Olaparib
Item
Specifications
Analysis Results
Conclusion
Appearance
Light yellow solid
Light yellow solid
conform
HNMR
Comply with the structure
Comply with the structure
Conform
LC-MS
Comply with the structure
Comply with the structure
Conform
Purity
≥95%
99.1%(254nm)
99.4%(220nm)
Conform
Conform
Melting point
N/A
N/A
N/A

my contact infomation is:
Whatsapp: 008615032102186
Email: bettyapi1989@163.com

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body

Advertisements